Purple Biotech Ltd

Explore Purple Biotech’s insider stake, option strategy, and its dual‑indication pipeline for osteoarthritis & hypertension—insightful analysis for risk‑tolerant investors.

CEO Efron Gil’s sizable insider holdings reveal strong confidence in Purple Biotech, yet market skepticism and potential dilution underscore the need for close watch on clinical milestones and pricing dynamics.

Explore how Lankry Shai’s insider options could dilute shareholders yet fuel Purple Biotech’s AI‑driven tri‑specific antibody platform, and what this means for investors.